Literature DB >> 24102356

Practitioner review: schizophrenia spectrum disorders and the at-risk mental state for psychosis in children and adolescents--evidence-based management approaches.

Paul A Tiffin1, Patrick Welsh.   

Abstract

BACKGROUND: Schizophrenia spectrum disorders are severe mental illnesses which often result in significant distress and disability. Attempts have been made to prospectively identify and treat young people viewed as at high risk of impending nonaffective psychosis. Once a schizophrenia spectrum disorder has developed, prompt identification and management is required.
METHODS: This article reviews the literature relating to the assessment and management of 'at-risk mental states' (ARMS) and the treatment of schizophrenia spectrum disorders in children and adolescents. A systematic search of the literature was undertaken using EMBASE, MEDLINE, PsycINFO databases for the period January 1970-December 2012.
RESULTS: Evidence suggests that young people fulfilling the ARMS criteria are at high risk of adverse mental health outcomes but that the majority do not develop nonaffective psychosis over the medium term. Although clinical trial findings have been inconsistent, psychosocial approaches, such as cognitive behaviour therapy, may reduce the risk of transition to psychosis and improve some symptoms, at least over the short term. The effectiveness of psychotropic medication for the ARMS is uncertain although there is accumulating evidence for potential adverse effects of antipsychotic medication, even at low dose, in this population. For the schizophrenias, clinical trial findings suggest that, as in adults, antipsychotics should be selected on the basis of side-effect profile although clozapine may be helpful in treatment refractory illness. There are almost no studies of psychosocial treatments for schizophrenia in young people under 18, and some caution must be exercised when extrapolating the findings of adult studies to younger individuals.
CONCLUSIONS: A stepped care approach to the ARMS in young people represents a plausible potential management approach for those at high risk of serious mental health problems. However, predictive models currently lack precision and should focus on accurately identifying those at high risk for a variety of poor outcomes who may benefit most from intervention. There is also an urgent need for age-specific research in the area of psychosocial treatments for children and adolescents with schizophrenia.
© 2013 The Authors. Journal of Child Psychology and Psychiatry © 2013 Association for Child and Adolescent Mental Health.

Entities:  

Keywords:  Schizophrenia; early recognition; prodrome; psychosis; risk syndrome

Mesh:

Year:  2013        PMID: 24102356     DOI: 10.1111/jcpp.12136

Source DB:  PubMed          Journal:  J Child Psychol Psychiatry        ISSN: 0021-9630            Impact factor:   8.982


  4 in total

1.  Clinical high risk for psychosis in childhood and adolescence: findings from the 2-year follow-up of the ReARMS project.

Authors:  Michele Poletti; Lorenzo Pelizza; Silvia Azzali; Federica Paterlini; Sara Garlassi; Ilaria Scazza; Luigi Rocco Chiri; Eva Gebhardt; Simona Pupo; Raballo Andrea
Journal:  Eur Child Adolesc Psychiatry       Date:  2018-12-01       Impact factor: 4.785

Review 2.  Clinical high risk for psychosis in children and adolescents: a systematic review.

Authors:  Jordina Tor; Montserrat Dolz; Anna Sintes; Daniel Muñoz; Marta Pardo; Elena de la Serna; Olga Puig; Gisela Sugranyes; Inmaculada Baeza
Journal:  Eur Child Adolesc Psychiatry       Date:  2017-09-15       Impact factor: 4.785

3.  Attenuated psychosis syndrome.

Authors:  M S Reddy
Journal:  Indian J Psychol Med       Date:  2014-01

4.  Motion energy analysis during speech tasks in medication-naïve individuals with at-risk mental states for psychosis.

Authors:  Ana Caroline Lopes-Rocha; Cheryl Mary Corcoran; Julio Cesar Andrade; Leonardo Peroni; Natalia Mansur Haddad; Lucas Hortêncio; Mauricio Henriques Serpa; Martinus Theodorus van de Bilt; Wagner Farid Gattaz; Alexandre Andrade Loch
Journal:  Schizophrenia (Heidelb)       Date:  2022-09-16
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.